PMID- 17157173
OWN - NLM
STAT- MEDLINE
DCOM- 20071127
LR  - 20061212
IS  - 0301-472X (Print)
IS  - 0301-472X (Linking)
VI  - 34
IP  - 12
DP  - 2006 Dec
TI  - Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in 
      hematopoietic stem cell recipients.
PG  - 1753-8
AB  - OBJECTIVE: In the hematopoietic stem cell transplantation setting, granulocyte 
      colony-stimulating factor (G-CSF) administration can reduce donor cell reactivity 
      in vitro, but the clinical significance of this phenomenon was only sparsely 
      defined. METHODS: We performed lymphocyte transformation tests in 28 related stem 
      cell donors pre and 5 days post G-CSF treatment, respectively, and correlated 
      proliferative responses of donor peripheral blood mononuclear cells with clinical 
      parameters in the corresponding recipients. RESULTS: In vitro reactions towards 4 
      mitogens and 12 recall antigens at day 5 post G-CSF administration were 
      predictive for the occurrence of chronic graft-vs-host disease (cGVHD). Here, 
      proliferative responses towards the mitogen anti-CD3 monoclonal antibody (OKT3) 
      above median were most informative; this threshold could be determined by 
      discrimination and receiver operating curve (ROC) analyses. In the whole cohort 
      (18 human leukocyte antigen [HLA]-identical and 10 partially mismatched 
      donor-recipient pairs), OKT3 responses predicted cGVHD with an odds ratio of 
      33.0, a sensitivity of 79%, and a specificity of 90%. A subgroup analysis of 
      HLA-identical pairs even yielded an odds ratio of 85.0. Furthermore, bivariate 
      analysis defined HLA compatibility and responses towards OKT3 as independent risk 
      factors for cGVHD (p = 0.02 and p = 0.0007, respectively). CONCLUSION: The 
      proliferative capacity of G-CSF-mobilized donor cells appears as a graft factor 
      that determines the future incidence of cGVHD in the corresponding recipient.
FAU - Lindemann, Monika
AU  - Lindemann M
AD  - Institute of Immunology, University Hospital, Essen, Germany.
FAU - Ottinger, Hellmut D
AU  - Ottinger HD
FAU - Elmaagacli, Ahmet H
AU  - Elmaagacli AH
FAU - Trenschel, Rudolf
AU  - Trenschel R
FAU - Rebmann, Vera
AU  - Rebmann V
FAU - Beelen, Dietrich W
AU  - Beelen DW
FAU - Grosse-Wilde, Hans
AU  - Grosse-Wilde H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Muromonab-CD3)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cell Proliferation/drug effects
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/*immunology/prevention & control
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Lymphocyte Activation/drug effects
MH  - Male
MH  - Middle Aged
MH  - Muromonab-CD3/*pharmacology
MH  - Predictive Value of Tests
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - *Tissue Donors
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2006/12/13 09:00
MHDA- 2007/12/06 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/05/29 00:00 [received]
PHST- 2006/07/31 00:00 [revised]
PHST- 2006/08/07 00:00 [accepted]
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
AID - S0301-472X(06)00490-5 [pii]
AID - 10.1016/j.exphem.2006.08.003 [doi]
PST - ppublish
SO  - Exp Hematol. 2006 Dec;34(12):1753-8. doi: 10.1016/j.exphem.2006.08.003.